Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes.

Running title: clonality and metastasis in endometriosis

Teresa H. Praetorius[1,2], Anna Leonova[2,3], Vivian Lac[2], Basile Tessier-Cloutier[2,4], Janine Senz[2], Tayyebeh M. Nazeran[2], Martin Köbel[5], Marcel Grube[1], Bernhard Kraemer[1], Paul J. Yong[2,3,6], Stefan Kommoss[1*], Michael S. Anglesio[2,3*]

Affiliations:

1) Department of Women's Health, Tübingen University Hospital, 72076 Tübingen, Germany
2) British Columbia's Gynecological Cancer Research Program (OVCARE), University of British Columbia, Vancouver General Hospital, and BC Cancer, Vancouver, BC, Canada, V5Z 4E6
3) Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada, V6H 3Z6
4) Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada, V5Z 1M9
5) Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada, T2N 2T9
6) BC Women's Centre for Pelvic Pain & Endometriosis, BC Women's Hospital and Health Centre, Vancouver, Canada, V6H 3N1

*Corresponding Authors (These authors contributed equally to this work):

Dr. Michael S. Anglesio, PhD
m.anglesio@ubc.ca; University of British Columbia, Robert HN Ho Research Centre; 2660 Oak Street, Vancouver, BC, Canada. V6H 3Z6

Prof. Dr. med. Stefan Kommoss
stefan.kommoss@med.uni-tuebingen.de; Department of Women's Health, Tübingen University Hospital, Calwerstraße 7, 72076 Tübingen, Germany

Abstract

Endometriosis symptoms are heterogeneous with controversy on whether it constitutes a single disease or multiple distinct types. Our previous work found recurrent somatic cancer-driver alterations in endometriosis; however, these have not been found ubiquitously. A handful of cases spread across studies also suggest mutations might be shared (clonal) between lesions of the same type. As current classification systems correlate poorly with symptoms or outcomes, somatic genomics may improve the current system. Here, we investigate heterogeneity of somatic cancer-driver mutations within patients and across endometriosis types.

We examined anatomically distinct types of endometriosis (ovarian, deep infiltrating, and superficial endometriosis) in 27 individual patients all of whom had at least two types of endometriosis. Specimens were analyzed using high-sensitivity targeted sequencing with orthogonal validation from droplet digital PCR and mutation-surrogate immunohistochemistry.

Results found 13/27 patients had informative somatic driver mutation in endometriosis, 9/13 had identical mutations across distinct lesions. Endometriomas tended to have a potential for higher mutational load, and this often resulted in functionally redundant driver mutations in same gene within the same lesions.

Our data are consistent with clonality across endometriosis

lesions regardless of subtype. Further the finding of redundancy in

mutations with the same gene and lesions is also consistent with

endometriosis representing an oligoclonal disease with

dissemination likely to consist of multiple epithelial clones

travelling together. this suggests the current anatomically defined

classification of endometriosis does not fully recognize the

etiology of the disease. A novel classification should take into

account genomic and other molecular features. These findings

could further contribute to development of a more personalized

endometriosis diagnosis and care.

Introduction

Endometriosis is a chronic estrogen-dependent inflammatory

disease defined by the presence of endometrial epithelial glands

and stroma outside the uterine lumen and a small but significant

risk of malignant transformation (1-3). It is estimated to affect up to

10% of biological females of reproductive age and can result in

severe adverse effects on quality of life and productivity (4, 5).

Clinical symptoms of endometriosis are diverse and include pelvic

pain, dysmenorrhea, dyspareunia, and infertility (2, 6). Three

major anatomically described types of endometriosis are

recognized: superficial peritoneal endometriosis (EM), deep

infiltrating endometriosis (DIE) and ovarian endometriomas

(OMA). In addition, rare types such as mass forming/tumorous or

iatrogenic forms also exist. Current classification systems such as

the revised American Society for Reproductive Medicine (rASRM)

scoring system and the ENZIAN classification for DIE are useful in

documenting surgical findings in a standardized manner.

However, they poorly correlate with the severity of symptoms and

fail to provide a prognostic tool concerning the treatment outcome

for pain or infertility (7, 8). Likewise, classification and staging of

endometriosis are based on clinical findings and surgical

presentation and do not include any information about the

molecular potential or microenvironment of these lesions.

Recent studies have now shown that multiple forms of

endometriosis harbor somatic cancer-driver alterations including

recurrent activating changes in *KRAS, PIK3CA, ARID1A* and

others (9-11). While it appears the underlying malignant potential

for the vast majority of lesions, despite the presence of recurrent

driver mutations, remains low (6), their ultimate function in the

pathobiology of endometriosis remains unclear. These findings

are particularly important to monitoring disease since somatic

alteration could be therapeutically targeted or tracked to examine

etiology and potential disease dissemination. The concept that

endometriosis disseminates is not novel. Endometriosis frequently

presents with multiple anatomical sites affected by lesions(12, 13);

recent findings confirm a high rate of coexistence between

OMA, EM, and DIE where only 2.3% of study had isolated

OMA (12). Along with current etiology largely attributing an

origin to endometrial tissues, all endometriosis lesions may well

have disseminated from a eutopic point of origin. This highlights

the importance of studying the mechanisms of clonal

dissemination and metastasis of endometriosis (11, 13, 14).

Nonetheless, there is little objective evidence in support of

widespread clonal dissemination of endometriosis tissues.

Clinical presentation of endometriosis is heterogeneous and it is

controversial whether endometriosis constitutes one disease entity

or whether independent types with different underlying

pathogenesis exist (15). As noted above somatic alteration could

be used to examine the spread and distribution of distinct

endometriosis clones within a given individual. Here we explored

the potential clonal relationship of endometriosis from 27 patients

with multiple anatomically separated lesions, and each having at

least two distinct types of endometriosis. Our initial objective was

assessment of clonality at the level of endometriosis anatomically

described types, asking questions such as: are mutations

frequently shared between lesions and/or between lesion types. If

they are not, this would suggest each anatomically defined type

represents a unique disease. If they are this would indicate

plasticity between types and/or that our understanding of

endometriosis types is currently insufficient.

Materials and Methods

Experimental subject details

Formalin-fixed and paraffin-embedded (FFPE) archival tissues

from 27 patients from the Tübingen University Hospital, Germany

were included. Inclusion criteria included histopathological

diagnosis of endometriosis, presentation of two or more types of

endometriosis (deep infiltrating, and/or superficial, and/or ovarian

endometrioma) in distinct anatomical locations, and lesions

estimated to be of sufficient size for macrodissection. Patients with

a history of, or co-existing, gynecological cancer were excluded.

Experiments were done at the University of British Columbia and

the University of Calgary. The project was conducted in

compliance with the Canadian Tri-Council Policy Statement on

Ethical Conduct for Research Involving Humans (TCPS2, 2018),

effort to obtain written informed consent was exercised for all

patients. Specimen from non-contactable patients (lost

contact/deceased) treated more than 5 years before the start of

the study were included under institutionally approved waiver of

consent (Tübingen University Hospital Research Ethics Board). All

institutions approved use of materials and associated clinical data

through local research ethics boards.

Sample processing and DNA extraction

FFPE specimens were sectioned onto glass slides, stained with

dilute hematoxylin and eosin, and manually enriched for

endometriosis glands and stroma by manual microdissection as

described previously (10, 16). DNA was extracted using the

ARCTURUS® PicoPure® DNA Extraction Kit (ThermoFisher

Scientific, USA) and quantitated using the Qubit 2.0 Fluorometer

(ThermoFisher Scientific, USA).

<u>Targeted sequencing</u>

DNA (45-75ng) was sequenced using a proprietary hypersensitive

cancer hotspot sequencing panel: FIND IT™, version 3.4 (Canexia

Health, Canada) (9, 10). This assay includes hotspots from 33

genes (10, 16) (Table S1). Mutations were considered "true", if

they were genuine hotspot mutations targeted by the FIND IT

assay and previously reported in the Catalogue of Somatic

Mutations in Cancer (COSMIC) (17), as well as prior observations

with validation (9, 10), including a probability score >0.8 and a

variant allele frequency (VAF) >0.8% (see Table S2A).

<u>Validation via droplet digital PCR</u>

Somatic mutations identified by targeted sequencing were

orthogonally validated through droplet digital polymerase-chain-

reaction (ddPCR) assays. In addition, selected alterations were

tested by ddPCR in all available lesions from a given patient if

they were observed either in any one lesion from a given patient

(subjected to the FIND IT panel assay), regardless of the results

obtained in other panel-tested lesions from the same patient and

including any specimens from the same patient that were initially

omitted from panel testing due to low DNA yield. Using previously

established methods (10, 16), extracted DNA was pre-amplified

for targets over 10 cycles then diluted before assembling the

ddPCR assay. Droplets were generated using the QX200 Droplet

Generator (Bio-Rad Laboratories, USA), amplified by thermal

cycling, and quantified using the QX2000 Droplet Reader (Bio-

Rad Laboratories, USA). As above alterations were considered

"true" if they passed the above noted probability and VAF

thresholds for targeted sequencing or were detected using ddPCR

above a droplet count set at the average of the negative control

specimens plus 3 times the standard deviation of negative

controls the relevant assay. See Table S3 for primer/probe details.

<u>ARID1A, PTEN and p53 Immunohistochemistry</u>

Immunohistochemistry (IHC) assays for ARID1A (18) , p53 (19,

20) and PTEN (10, 16) (Table S3) were used as surrogate for

somatic alterations following established standards for staining

and scoring. ARID1A was stained on Dako Omnis automated

immunostainer (Agilent Technologies, USA) or Ventana

BenchMark Ultra autostainer (Ventana Medical Systems, USA)

the ARID1A rabbit polyclonal antibody, HPA005456 (Sigma-

Aldrich). PTEN was stained on Ventana Discovery Ultra (Ventana

Medical Systems, USA) using the rabbit monoclonal antibody,

138G6 (Cell Signaling, USA). p53 was stained on Dako Omnis

(Agilent Technologies, USA) using the p53 mouse monoclonal

antibody DO-7 (GA61661-2; Agilent Technologies, USA). Slides

were scored by pathologists TMN, and/or BTC, and/or MK.

<u>Calling Criteria</u>

Calling criteria was applied to all detected alterations as noted

above, including a probability score >0.8 and VAF >0.8% for panel

sequencing and individual droplet count thresholds for each

ddPCR assay(10, 16).

Immunohistochemistry assays were performed and scored

according to established standards, briefly ARID1A loss if nuclear

staining was absent in endometriosis epithelium cells and internal

control (stroma) was intact (18). Mutant p53 (p53abn) if high

intensity positive staining was observed in 10 or more adjacent

cells in the epithelial cyst wall of endometriosis or complete

absence of staining in the entire cyst wall, while maintaining a

normal type pattern in surrounding tissue (19, 20). PTEN loss if

cytoplasmic and nuclear staining was absent in endometriosis

epithelium cells and internal control (stroma) was intact (10, 16).

Statistics

Student's t-test was performed to compare the affected genes and

lesion types. However, given our limited sample size, they

remained non-significant.

Results

We examined 73 endometriosis lesions from 27 patients with a

mean age of 34.9 years (23-45 years; Table S2; Figure S1). 53

lesions were subjected to panel-based sequencing with validation

of selected alteration by ddPCR, 6 additional samples included in

ddPCR validation only. In cases with sufficient material, lesions

were also subjected to mutation surrogate IHC for PTEN (66

interpretable), ARID1A (66 interpretable) and p53 (47

interpretable). A total of 27/59 (45.8%) lesions from 13/27 (48%)

cases were confirmed to have identifiable somatic cancer-driver

mutations. It should be noted that lesion with mutations observed

near, but below, our positive detection thresholds were considered

negative, as were alteration which appeared above threshold in

panel sequencing data but failed to exceed detection threshold in

ddPCR. For example, in a 14th case panel testing suggested

alteration but these fell below detection threshold at the ddPCR

stage (case 7; Table S2). Nonetheless, potential interpretation for

sub-clonal/sub-detection threshold alterations is discussed in a

limited context where relevant.

Amongst the panel screened lesions, we found nearly half of the

tested cases had at least one mutation; where identical assays

were applied, *PIK3CA* alterations were the most common (27

hotspot mutations, affecting 12/53 lesions in 6 cases), followed by

KRAS (16 hotspot mutations, affecting 15 lesions in 6 cases) and

CTNNB1 (10 hotspot mutations, affecting 7/53 lesions in 4 cases;

Figure 1). In contrast to the overall frequency of alterations more

lesions were affected by KRAS alteration overall. This trend was

the same regardless of lesion type (Figure 1D) or if summarizing

by fraction of affected cases (Figure 1E). Further, OMA tended to

have a higher proportion of lesions affected by somatic cancer-

driver alterations and subsequently higher mutation load than

other lesion types (Figure 1, Table S2).

Alterations were less frequently observed in *NRAS* (6 mutations,

6/53 lesions, 4 cases), *ERBB2* (2 mutations, 2/53 lesions, 1 case)

and *EGFR* (2 mutations, 2/53 lesions, 2 cases). Although our

cohort had insufficient numbers to support strong associations, we

noted many lesions, predominantly amongst OMA, contained

multiple mutations in the same genes. OMA also tended to have

higher mutational burden on average (amongst our screened

panel mutations). No samples had identifiable p53-abnormal

staining pattern (0/47 lesions), PTEN loss was observed in 5

cases (8/66 lesions), and ARID1A loss was observed in 1 case

(2/66 lesions).

Immunohistochemical data is inconclusive with respect to

clonality, and similar abnormal patterns were considered in

support of mutation findings. Our mutation data suggested a

single *TP53* alteration but no abnormal p53 pattern was observed

by IHC, we considered this as a false positive (case 22; Table

S2A). We observed no *PTEN* mutations in sequencing data

despite evidence of loss in PTEN protein expression by IHC in

8/66 lesions (Table S2B), however only a small number of

hotspots are covered in panel sequencing. In one case (case 2)

with PTEN loss in multiple lesions other somatic (clonal) point

mutations were shared between the PTEN-loss affected lesions

(Table 1; Table S2A). Case 3 showed loss of ARID1A protein

consistent with loss-of function somatic mutation (18) in both an

EM and OMA samples from this patient (Figure 2). Unfortunately,

insufficient tissue was available to validate any mutation in the EM

sample, however, the *PIK3CA* (p.Met1043Ile) and *KRAS*

alterations were shared across all other lesions from this case.

Altogether we observed clonality between at least two

endometriotic lesions in 8 out of 13 informative cases (Table S2A;

Figure S2).

For ease in presenting results details we have divided informative

cases into two categories. Simple cases, with only one or two

altered genes and/or one or two informative lesions, and complex

cases, with larger numbers of alterations across lesions and

lesions with functionally redundant mutations.

<u>Simple cases</u>

We annotated 7 cases as simple (Table 1) based on presence of

up to 2 alterations and no functionally redundant (i.e. equivalent

activating change resulting from different nucleotide and/or amino

acid substitution in the same gene) mutations seen in same

lesion. We identified and validated shared mutations across

multiple lesions and different types in 3 cases (Figure S2). Case 6

shared mutations in *PIK3CA* between EM and DIE. The other two

cases shared mutations in *KRAS*. Case 19 shared a p.Gly12Ser

mutation between an OMA and a DIE. Case 21 shared a

p.Gly12Asp between an OMA and three different DIE lesions.

In 4 cases mutations were uninformative with respect to clonality

(Figure S2), 3 of which had mutations observed in only a single

lesion (*KRAS* or *EGFR*). In the last (Case 9) we detected different

mutations in the lesions, consisting of different *KRAS* alterations

as well as one *PIK3CA* alteration - none shared between lesions.

<u>Complex Cases</u>

All six cases in this complex category (Table 1) showed evidence

of a clonal relationships between lesions and in each case at least

one lesion showed multiple functionally redundant hotspot

alterations (Figure S2; Figure 2 and 3). In one case we observed

identical somatic alterations between EM and DIE lesions (case

13), in 4 cases between DIE and OMA (cases 1, 2, 3, 8; Figure 2)

and in one case between all three types (case 4; Figure 3).

Functional redundancy was most common with *PIK3CA*, seen in

12 lesions across 5 cases. Up to 5 simultaneously observed

activating changes in *PIK3CA* were validated in a single lesion

(case 2). In 4/5 cases with *PIK3CA* mutations we further observed

co-existing alterations in *CTNNB1*, where at least one was shared

across multiple sites/types within the affected patient. In 3/4 cases

redundancy in *CTNNB1* was seen with up to 3 simultaneously

observed alterations in the same lesion (case 1 OMA; case 2 DIE;

and case 4 shared between DIE and EM). The fourth case had

only a single observed (*PIK3CA*) co-existing *CTNNB1* alteration

shared between an OMA and a DIE (case 8). A single complex

case with a *PIK3CA* alteration had no co-existing *CTNNB1*

alterations, at least within our panel assay and therefore no further

testing by ddPCR was done. A single case (Case 13) lacking

PIK3CA alteration did have multiple redundant *CTNNB1*

alterations, with at least one shared between DIE and EM (an

OMA specimen from the same case had insufficient material for

testing).

KRAS alterations were seen in 5 of 6 complex cases, only case 1

in this category showed multiple redundant activating changes

(p.Gly12Val in DIE, p.Gly12Ser in both DIE and OMA). This

particular case also had multiple redundant mutations in *PIK3CA*

(4/4 shared), and *CTNNB1* (3/3 shared), as well as an *NRAS*

(shared) alteration. As *PIK3CA*, *CTNNB1* and *KRAS* alteration

were all relatively common we saw co-existence between these in

3/6 cases. The single case (Case 13) that lacked *PIK3CA*

alterations had both *CTNNB1*, *EGFR* and *ERBB2*, shared

between DIE and EM. A *KRAS* mutation was detectable in this

case only in the DIE.

NRAS alteration were detected in 4 of 6 complex cases, no case

showed multiple redundant alterations of *NRAS* itself but overlaps

with *KRAS* mutations were present. In 3 cases (Cases 1, 2, 8) an

NRAS alteration was shared between an OMA and a DIE lesion.

In case 4 we detected one *NRAS* alteration shared between an

OMA, a DIE lesion and an EM.

ERBB2 alterations were detected in 2 of 6 complex cases, one

alteration shared between an OMA and two DIE lesions (case 3)

as well as the shared mutation in case 13 as noted above. An

EGFR alteration was also shared between the two analyzed

lesions in case 13.

326   Discussion

We examined a total of 73 lesions from 27 individuals affected by

endometriosis, we focused on within patient heterogeneity – a

largely overlooked feature amongst current genomic studies on

endometriosis. Cases were specifically selected to have multiple

anatomical sites affected as well as multiple "types" of

endometriosis including EM, DIE and OMA. Using a high-

sensitivity, and error-correcting, sequencing technology followed

by validation and additional screening with ddPCR we identified

somatic cancer driver alterations in lesions from 13 patients. A

total of 27 lesions had at least one driver alteration, 7 lesions had

more than 5.

We found evidence of identical alteration across lesions in 10

individuals, all of which spanned more than one type of

endometriosis. The relatively commonplace finding of identical

mutations across lesions suggests that at least a subset is clonal,

sharing a common ancestor. Given our present data set the

order/directionality of dissemination cannot be determined

(Figures 2 and 3). We found that in 9 lesions there appeared to be

multiple functionally redundant alterations, which is consistent with

individual lesions being oligoclonal. Functionally redundant

mutations were seen in *PIK3CA*, *KRAS*, and *CTNNB1*. This

extended to 6 of 13 cases with observed somatic alterations. In 3

of these cases the redundant alterations were identified in two or

more, suggesting dissemination likely involved multiple epithelial

clones traveling together.

Examining the specific prevalence of mutations across lesions we

observed more *PIK3CA* mutations than any other. Amongst

informative cases OMAs tended to have a higher average

mutation burden, at least within our panel, with OMA lesions from

cases 1, 2, 3 having multiple activating *PIK3CA* and/or *CTNNB1*

(and others) driving this average mutation burden up. When

examining prevalence at a per lesion or per individual level we

found more lesions, and more individuals, to be affected by

somatic KRAS mutations. Despite a higher mutation burden within

a subset of OMAs, DIE appeared to have a wider range of

mutations from our panel with *EGFR* and *ERBB2* mutations seen

only in DIE.

Our study is unique in examination of a modest number of co-

existing lesions. Particular strengths include enrichment of

endometriosis glands and stroma, the use of proven high-

sensitivity and specificity digital sequencing methods, and

orthogonal validation for the majority of alterations (21). We

elected to be relatively conservative in calling mutations, however,

it should be noted that a number of alterations were found to be

just below detection thresholds, if a single assay was done, or

both just above on panel sequencing and just below on ddPCR. In

such cases we considered alteration to be negative/unvalidated.

In sampling tissue for sequencing assays and subsequent ddPCR

we took sequential tissue sections from a block for enrichment

and analysis, often requiring re-sampling of tissue for validation.

Hence, we must consider that in a small population of cells, such

as a microscopic glands of endometriosis epithelium, it is possible

that the proportion of mutation harboring cells changes as a

specimen is sectioned such that it would genuinely yield a fraction

of cells below a detection threshold in one sampling and above a

detection threshold in another. If we were to be more liberal with

assessment of ground-truth mutations our overall conclusion

would not change though it would suggest greater complexity and

more examples of oligoclonal dissemination throughout our

cohort.

Potential weaknesses include the use of macrodissection instead

of laser capture microdissection. In this context we cannot reliably

use the variant allele frequency for anything other than binary

presence or absence assessment of somatic alterations. IHC

observations suggested somatic alteration were exclusive to the

epithelium, similar to prior observation with laser-capture

microdissection, though this was not explicitly monitored in

sequencing experiments. In addition, we used only a relatively

limited panel assay to screen for mutations. Therefore, while we

can make suggestions about potential lineage of samples with

informative mutations, we are missing considerable data about the

un-analyzed genome. Thus, this should be considered as a

minimum estimate of clonality. We cannot strictly conclude that

any cells or lesions (within a given patient) that do not share

mutations with those found within our panel are of unrelated

lineage. Nonetheless, the presence of functionally redundant

alterations (multiple *KRAS, PIK3CA*, and *CTNNB1* alterations)

does suggest at the very least divergence of subclones within

lesions is likely.

Broad dissemination and metastasis in general are common

features of advanced cancers but are not typical for a benign

neoplastic disease. Endometriosis knowingly shares many

characteristics with tumors, and it is also associated with the most

lethal gynecologic cancer: ovarian carcinomas, where

endometriosis is both a risk factor and proven precursor lesion for

both endometrioid and clear cell ovarian carcinomas.

All major anatomically described types of endometriosis can

harbor recurrent somatic cancer-driver alterations. Our findings

validate a modest spectrum of driver alterations, as has been

described previously (9, 10, 22). While single cases have been

described to share alteration between lesions of the same type (9,

14), we provide considerable evidence that shared lineage

between lesions is common, not only between lesions of the same

type, but across anatomically defined lesion types. If we consider

the likelihood of clonal dissemination of endometriosis, then

anatomical lesion type descriptions alone are insufficient and

should be supplemented with molecular characterizations – albeit

which features are clinically useful is not yet established.

In recent years there has been a shift away from seeing

endometriosis as one disease entity. In addition to biochemical

variations, considerable efforts are being applied to identify

subtype-specific genomic alterations. This ongoing trajectory of

thought has spiked research of endometriosis biomarkers and

subtype-tailored treatment. However, here we demonstrate that

sampling and comparing lesions from different individuals based

solely upon anatomical classification, may yield inadequate

results. Our data supports the presence of identical mutations

among lesions of the same individual and suggests the clonal

dissemination and metastasis mechanism of disease spreading.

This underscores the need for molecular classification when

designing personalized endometriosis care.

To make significant impact the next generation of endometriosis-

genomic studies must apply high stringency methods, with

appropriate enrichment of tissues, orthogonal validation and/or

error correcting sequencing technologies, and most critically be

coupled to large clinical data registries conforming to accepted

standards in phenotyping data (21) - such as those promoted by

WERF-EPHect (23, 24). Early studies on somatic genomics of

endometriosis have suggested relatively few alterations per lesion

(9, 11, 22, 25). However, this work suggests endometriosis may

have moderate genomic complexity. Any future study wishing to

correlate genomic heterogeneity with the clinical phenotypic

spectrum may be complex, it is not sufficiently informative to

sample only one lesion per patient for mutation testing. Accurate

assessment of somatic mutation profiles may require a significant

fraction of lesions are excised and tested at surgery (rather than

ablated without biopsy).

In addition to the already appreciated complexity of endometriosis,

it has now become even more evident that disease presentation is

unique and may depend on many factors. This work has also

shown that OMAs had the highest mutation burden, while DIE

lesions were associated with wider range of mutation. Considering

previous work in the field (26-29), this data is consistent with

observations that lesion microenvironment may be more

permissive for expansion of multiple clones, and hence the higher

risk of malignant transformation (30). DIEs might be surrounded

by a more restrictive microenvironment conditions resulting in

fewer clones and lower malignant potential. As a specific example

of clonal expansion, we observed that multiple redundant *PIK3CA*

activating mutation were prevalent in OMAs. These *PIK3CA*

alterations are also common to endometriosis-associated cancers

and appear necessary (in combination with ARID1A) for the

generation of a representative clear cell ovarian carcinomas

model in mice (31), together suggesting they are critical in

underlying malignant potential. Extraovarian microenvironment

restriction on malignant potential has been suggested as a

potential mechanism for the generally favorable outcomes

observed in low-stage synchronous (yet metastatic) endometrioid

ovarian and endometrial carcinomas – etiologies tightly linked to

endometriosis(32).

As we move forward, consideration should be made to determine

if patient-wide endometriosis mutation profiles should include

ranking of allele frequency, dissemination/spread, clonality across

lesions and anatomic types. Phenotyping clinical characteristics

could also monitor eutopic endometrium (16) and pathway

enrichment across mutations. Intra-lesion spatial heterogeneity

(such as in a large OMA or deep nodules) may warrant study

especially in relapse/persistent chronic disease and those

associated with malignant progression. Simple binary assessment

now seems insufficient and modeling with machine learning

approaches may be paramount to identify associations between

heterogeneous molecular profiles and heterogeneous clinical

presentation.

Figure Legends

Figure 1: Fraction of cohort affected by somatic hotspot mutations

detected in panel sequencing. (A) Overall split of cases with at

least one lesions having at least one somatic cancer-driver

alteration. (B) Numbers of detected somatic mutations, split by

affected gene, across our entire cohort. (C) Fraction of mutation

affected lesions, split by mutation type. (D) Fraction of mutation

affected lesions, split by lesion type. (E) Fraction of mutation

affected lesions, summarized by fraction of affected cases.

Figure 2: Clonal relationships in Case 3 patient presenting with

DIE of the vagina, DIE of the cul-de-sac, an OMA of the left ovary,

and EM of the rectum. (A) Detected somatic alteration from

sequencing and mutation surrogate IHC suggest identical/clonal

alteration in *KRAS*, *ERBB2*, and *PIK3CA* (p.Met1043Ile) between

OMA and two anatomically distinct lesions of DIE. Additional

PIK3CA alterations are also visible in the OMA and vaginal DIE.

Heterogeneous loss of ARID1A is observed in only the OMA and

EM (insufficient material was available for mutation testing in EM).

(B) Three possible dissemination models explaining the mutational

pattern: (1) top panel illustrates a linear pattern wherein clones

from the cul-de-sac travel to the vagina and acquired additional

alterations in *PIK3CA*. Subsequent transfer of all clones to the

ovary where subclonal-ARID1A loss occurs. It may further be

speculated that the EM resulted from a transfer of clones between

the vaginal DIE and OMA (as the initial site for ARID1A loss) or

subsequent spread after clones established on the ovary. Given

the lack of mutational data on the EM it may also be entirely

independent. (2) middle panel illustrates an example where a

complex set of clones exist at the ovary and only a subset of these

break-off and colonize vaginal, cul-de-sac and EM/rectal sites.

Finally, (3) Lower panel illustrates parallel dissemination from the

cul-de-sac lesion to both the vaginal and ovarian sites. Herein we

may consider sub-threshold signal from ddPCR of p.Arg88Gln,

p.Glu545Lys and p.Gly1049Ser PIK3CA alteration (Table S2) as

weak evidence of emerging/undetectable clones that

subsequently expand post-transfer of cells to both vagina and

ovary. In this model again, the OMA acquires loss-of function

ARID1A alterations. Additional possibilities may also explain the

mutational patterns. (C-D-E) photomicrographs showing ARID1A

IHC results including regions of loss (surrogate for loss-of function

mutation; black arrows) and normal (retained nuclear staining; red

arrows) in endometriosis epithelium.

Figure 3: Clonal relationships in Case 4 patient presenting with

DIE of the rectum, EM of the cul-de-sac and an OMA on the left

ovary. (A) Detected somatic alteration from sequencing suggest

all variants are shared between DIE and EM lesions. In contrast

the ovarian lesion shares only 1 *PIK3CA* and 1 *KRAS* alteration

with the other two and has no (detected) unique changes. (B)

Three possible dissemination models explaining the mutational

pattern: (1) top panel illustrates a linear model wherein clones

from the ovary travel to the rectum, expand and acquire additional

alteration. Cells from the DIE containing all clones then seed the

EM on the Cul-de-sac. (2) middle panel illustrates another linear

model of dissemination wherein a complex clonal population at the

Rectum seed the cul-de-sac. Subsequently only a subset of these

clone travel to and populate the ovary. Finally, (3) illustrates a

differing model of spread wherein a complex clonal population at

the Rectum seed the cul-de-sac with all clones. Only a subset with

a single *PIK3CA* and *KRAS* altered clone break-off to the ovary

(or alternatively only a subset with these specific alterations can

colonize the ovary).

Tables

Table 1: Cohort Overview. Each cell shows the number of lesions

available and tested from the noted anatomical site/type (number

in brackets denote lesions were not tested in panel sequencing).

Blue cell = shared alteration within case/between lesions marked

by blue cells in table (cells not in blue were uninformative/did not

show evidence of clonality with any other lesion from the given

case), Grey lines/cases were entirely uninformative (no mutation

detected in panel sequencing from any tested lesion).

Abbreviations: DIE= Deep infiltrating endometriosis, EM=

superficial endometriosis, OMA= endometrioma

References

1. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol **124**, 164-9 (2012). https://10.1016/j.ygyno.2011.10.001

2. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med **382**, 1244-56 (2020). https://10.1056/NEJMra1810764

3. Giudice LC. Clinical practice. Endometriosis. N Engl J Med **362**, 2389-98 (2010). https://10.1056/NEJMcp1000274

4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am **24**, 235-58 (1997).

5. Bulun SE. Endometriosis. N Engl J Med **360**, 268-79 (2009). https://10.1056/NEJMra0804690

6. Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol **10**, 261-75 (2014). https://10.1038/nrendo.2013.255

7. Johnson NP, Hummelshoj L, Adamson GD*, et al.* World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod **32**, 315-24 (2017). https://10.1093/humrep/dew293

8. American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril **67**, 817-21 (1997).

9. Anglesio MS, Papadopoulos N, Ayhan A*, et al.* Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med **376**, 1835-48 (2017). https://10.1056/NEJMoa1614814

10. Lac V, Verhoef L, Aguirre-Hernandez R*, et al.* Iatrogenic endometriosis harbors somatic cancer-driver mutations. Hum Reprod **34**, 69-78 (2019). https://10.1093/humrep/dey332

11. Suda K, Nakaoka H, Yoshihara K*, et al.* Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium. Cell Rep **24**, 1777-89 (2018). https://10.1016/j.celrep.2018.07.037

12. Piriyev E, Schiermeier S, Romer T. Coexistence of endometriomas with extraovarian endometriosis and adhesions. Eur J Obstet Gynecol Reprod Biol **263**, 20-4 (2021). https://10.1016/j.ejogrb.2021.05.044

13. Exacoustos C, De Felice G, Pizzo A, *et al.* Isolated Ovarian Endometrioma: A History Between Myth and Reality. J Minim Invasive Gynecol **25**, 884-91 (2018). https://10.1016/j.jmig.2017.12.026

14. Suda K, Cruz Diaz LA, Yoshihara K, *et al.* Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci, (2020). https://10.1111/cas.14507

15. Montgomery GW, Giudice LC. New Lessons about Endometriosis - Somatic Mutations and Disease Heterogeneity. N Engl J Med **376**, 1881-2 (2017). https://10.1056/NEJMe1701700

16. Lac V, Nazeran TM, Tessier-Cloutier B, *et al.* Oncogenic mutations in histologically normal endometrium: the new normal? J Pathol **249**, 173-81 (2019). https://10.1002/path.5314

17. Forbes SA, Bindal N, Bamford S, *et al.* COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res **39**, D945-50 (2011). https://10.1093/nar/gkq929

18. Khalique S, Naidoo K, Attygalle AD, *et al.* Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. J Pathol Clin Res **4**, 154-66 (2018). https://10.1002/cjp2.103

19. Kobel M, Piskorz AM, Lee S, *et al.* Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res **2**, 247-58 (2016). https://10.1002/cjp2.53

20. Kobel M, Ronnett BM, Singh N, *et al.* Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol **38 Suppl 1**, S123-S31 (2019). https://10.1097/PGP.0000000000000488

21. Yong PJ, Talhouk A, Anglesio MS. Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping. Reprod Sci, (2021). https://10.1007/s43032-020-00451-9

666　22.　Noe M, Ayhan A, Wang TL, Shih IM. Independent
667　　　　development of endometrial epithelium and stroma within
668　　　　the same endometriosis. J Pathol, (2018).
669　　　　https://10.1002/path.5082
670

23.　Fassbender A, Rahmioglu N, Vitonis AF*, et al.* World
Endometriosis Research Foundation Endometriosis
Phenome and Biobanking Harmonisation Project: IV.
Tissue collection, processing, and storage in endometriosis
research. Fertil Steril **102**, 1244-53 (2014).
https://10.1016/j.fertnstert.2014.07.1209
677

678　24.　Rogers PA, Adamson GD, Al-Jefout M*, et al.* Research
679　　　　Priorities for Endometriosis. Reprod Sci **24**, 202-26 (2017).
680　　　　https://10.1177/1933719116654991
681

682　25.　Bulun SE, Wan Y, Matei D. Epithelial Mutations in
683　　　　Endometriosis: Link to Ovarian Cancer. Endocrinology
684　　　　**160**, 626-38 (2019). https://10.1210/en.2018-00794
685

686　26.　Artemova D, Vishnyakova P, Khashchenko E*, et al.*
687　　　　Endometriosis and Cancer: Exploring the Role of
688　　　　Macrophages. Int J Mol Sci **22**, (2021).
689　　　　https://10.3390/ijms22105196
690

691　27.　Olkowska-Truchanowicz J, Bialoszewska A,
692　　　　Zwierzchowska A*, et al.* Peritoneal Fluid from Patients with
693　　　　Ovarian Endometriosis Displays Immunosuppressive
694　　　　Potential and Stimulates Th2 Response. Int J Mol Sci **22**,
695　　　　(2021). https://10.3390/ijms22158134
696

697　28.　Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to
698　　　　immunotherapy of ovarian clear cell carcinoma: Unique
699　　　　opportunities for management. Gynecol Oncol **151**, 381-9
700　　　　(2018). https://10.1016/j.ygyno.2018.09.001
701

702　29.　Lai CR, Hsu CY, Chen YJ*, et al.* Ovarian cancers arising
703　　　　from endometriosis: a microenvironmental biomarker study
704　　　　including ER, HNF1ss, p53, PTEN, BAF250a, and COX-2.
705　　　　J Chin Med Assoc **76**, 629-34 (2013).
706　　　　https://10.1016/j.jcma.2013.07.008
707

708　30.　Saavalainen L, Lassus H, But A*, et al.* Risk of Gynecologic
709　　　　Cancer According to the Type of Endometriosis. Obstet
710　　　　Gynecol, (2018). https://10.1097/AOG.0000000000002624
711

712　31.　Chandler RL, Damrauer JS, Raab JR*, et al.* Coexistent
713　　　　ARID1A-PIK3CA mutations promote ovarian clear-cell
714　　　　tumorigenesis through pro-tumorigenic inflammatory

715   cytokine signalling. Nat Commun **6**, 6118 (2015).
716   https://10.1038/ncomms7118

717
718   32.   Anglesio MS, Wang YK, Maassen M*, et al.* Synchronous
719   Endometrial and Ovarian Carcinomas: Evidence of
720   Clonality. J Natl Cancer Inst **108**, (2016).
721   https://10.1093/jnci/djv428
722

723   Acknowledgements

The authors thank all the study participants who contributed to this

study. We further recognize the invaluable contributions of Prof.

Dr. Sara Y. Brucker for continuous support of international

collaborations between the University Hospital Tübingen and the

University of British Columbia, as well as PD Dr. Annette Staebler

and the staff of the Institute of Pathology, University Hospital

Tübingen for facilitating access to pathology archives.

Funding was provided by Canadian Institutes of Health Research

(Early Career Investigator Grant in in Maternal, Reproductive,

Child & Youth Health to MS Anglesio). M Köbel received support

through the Calgary Laboratory Services research support fund

(RS19-609). MS Anglesio is funded through a Michael Smith

Foundation for Health Research Scholar Award (18274) and the

Janet D. Cottrelle Foundation Scholars program (managed by the

BC Cancer Foundation). This project received technical and data

management support from Calgary Laboratory Services and the

Genetic Pathology Evaluation Centre (GPEC). GPEC receive core

support from BC's Gynecological Cancer Research team

(OVCARE), and the VGH+UBC Hospital Foundation. M Köbel

was supported by internal research support (RS19-621). No

funder had any role in the study design, collection of data,

recruitment or participants, interpretation of results, manuscript

content, or decision to publish.

748   Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Ethics approval/consent to participate

All work was done in compliance with the Canadian Tri-Council

Policy Statement (TCPS2 2018) on ethical conduct for research

involving humans. Effort to obtain written informed consent was

exercised for all patients. Specimen from non-contactable patients

(lost contact/deceased) treated more than 5 years before the start

of the study were included under institutionally approved waiver of

consent (Tübingen University Hospital Research Ethics Board).

Research Ethics Boards of all participating institutions approved

the study and use of materials.

Author contributions

MSA and SK designed the study and concept. THP, MG, BK, and

SK identified candidate patients and obtained consent. THP, VL,

and JS processed and enriched samples and conducted

molecular experiments. BTC, TMN and MK conducted and scored

immunohistochemical experiments and reviewed/confirmed

endometriosis pathology. THP, JS, and MSA analyzed and

interpreted data. THP, AL, and MSA wrote the original draft. PJY,

BK, SK reviewed finding and all authors approved the draft

manuscript. Final draft was completed by AL and MSA.

Funding

This study received funding from the Canadian Institutes of Health

Research, the Michael Smith Foundation for Health Research, the

Janet D. Cottrelle Foundation, and the Calgary Laboratory

Services Research Support Fund.

Data availability

All data generated are available in this manuscript and

supplemental documents. Access to unprocessed/raw data from

the authors will be made available upon request, subject to REB

approval and applicable privacy laws.

A

B

C

E

D

Figure 1

A

| Case 3 Detected Alterations | | | | | |
Gene	Hotspot	OMA Left ovary	DIE (v) Vagina	DIE (c) Cul-de-sac	EM Rectum
PIK3CA	p.Glu545Lys	X	X		Insufficient size for sequencing
PIK3CA	p.Gly1049Ser	X	X		
PIK3CA	p.Arg88Gln	X	X		
PIK3CA	p.Met1043Ile	X	X	X	
KRAS	p.Gly12Asp	X	X	X	
ERBB2	p.Ser310Phe	X	X	X	
ARID1A IHC		Loss in atypical endometriosis			Hetero-geneous loss

B

(1) DIE(c) Cul-de-sac → DIE (v) Vagina → OMA Left ovary

(2) OMA Left ovary → OMA Rectum +? ; DIE(c) Cul-de-sac ; DIE (v) Vagina

(3) DIE(c) Cul-de-Sac → DIE (v) Vagina ; OMA Left ovary

C — Case 3 (OMA)

D — Case 3 (OMA)

E — Case 3 (EM)

Figure 2

A

Case 4 Detected Alterations				
Gene	Hotspot	DIE Rectum	OMA Left ovary	EM Cul-de-sac
PIK3CA	p.Glu542Lys	X		X
PIK3CA	p.Glu545Lys	X		X
PIK3CA	p.Gly1049Ser	X		X
PIK3CA	p.Met1043Ile	X	X	X
NRAS	p.Gly13Asp	X	X	X
CTNNB1	p.His36Tyr	X	X	X
CTNNB1	p.Gly34Glu	X		X
KRAS	p.Gly12Asp	X	X	X

B

Figure 3

Table 1 - Cohort overview

Category	Case ID	DIE: appendix	DIE: bladder	DIE: cul-de-sac	DIE: left sacrouterine ligament	DIE: rectovaginal septum	DIE: rectum	DIE: right psoas	DIE: right sacrouterine ligament	DIE: right pelvic wall	DIE: left pelvic wall	DIE: right pararectal space	DIE: right fossa ovarica	DIE: sigmoid	DIE: incisional	DIE: vagina	DIE: umbilicus	EM: bladder	EM: cul-de-sac	EM: rectum	EM: right abdominal wall	EM: right pelvic wall	EM: left pelvic wall	EM: right sacrouterine ligament	EM: left sacrouterine ligament	EM: colon	EM: right ovary	EM: left pararectal space	OMA: left ovary	OMA: pararectal space	OMA: right ovary	Grand Total
Complex Cases	1						1																								1	2
	2						1																								1	2
	3			1											1						[1]								1			4
	4						1												1										1			3
	8	1																						[1]	[1]				1			4
	13		1																			1							[1]			3
Simple Cases	6								1														1									2
	9	1																													1	2
	19													1																1		2
	20				1													1														2
	21		1		1	1			[1]																				1		1	6
	22				1				1														1									3
	24				1	1		1										[1]														4
Uninformative Cases	5						1																					1				2
	7														1								1									2
	10		1																							[1]						2
	11													1;[1]															[1]			3
	12		1																										1			2
	14													1															1			2
	15											1	[1]																1			3
	16					1																									1	2
	17															1			1													2
	18	1																													1	2
	23															1															1	2
	25																1		1										1			3
	26										1									[1]												2
	27						1		[1]	[1]								[1]									1					5
Grand Total		3	4	1	4	3	5	1	4	1	1	1	1	4	2	2	1	3	3	1	1	1	3	1	1	1	1	1	10	1	7	73

Each cell shows the number of lesions available and tested from the noted anatomical site/type (number in brackets denote lesions were not tested in panel sequencing and detected only in ddPCR). Blue cell = shared alteration within case/between lesions marked by blue cells in table (cells not in blue were uninformative/did not show evidence of clonality with any other lesion from the given case), Grey lines/cases were entirely uninformative (no mutation detected in panel sequencing from any tested lesion). Abbreviations: DIE= Deep infiltrating endometriosis, EM= superficial endometriosis, OMA= endometrioma